Skip to content
Sign in
European CDMOs compared · 2026 census

CDMOs in Poland: 11 compared (2026)

11 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Poland. None has revenue over €1bn. 1 sit between €250m and €1bn and 10 are smaller or niche.

By ownership: 4 family-owned, 6 listed and 1 state-owned. The most common capabilities are biologics and biosimilars (8), small-molecule API (4), monoclonal antibody (4), sterile fill-finish (3) and mRNA and LNP (2). 2 of the 11 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 11 in the interactive mapAll 255 European CDMOs

11 companies

CDMOs in Poland

CompanyHQOwnershipSizeRevenue (as reported)ModalitiesData
Adamed PharmaPieńkówFamily-ownedTier 2>PLN 1.6 bn (2023)Small-molecule API, Oral solid dosemedium
BiotonAmong the world's top-eight commercial manufacturers of recombinant human insulin.WarsawListedTier 3n/dBiologics and biosimilars, Sterile fill-finishmedium
Celon PharmaŁomiankiListedTier 3PLN 207 m (2024)Small-molecule API, mRNA and LNP, Biologics and biosimilarshigh
MabionPivoted from biosimilar developer to biologics CDMO; anchor Novavax COVID-antigen contract + Sartorius cooperation.Konstantynów ŁódzkiListedTier 3n/d (Novavax-driven, volatile)Biologics and biosimilars, Monoclonal antibody, Sterile fill-finishlow
Polfa TarchominState-owned; anti-infectives + insulin + ampoules/vials/lyo.WarsawState-ownedTier 3n/dSmall-molecule API, Biologics and biosimilars, Sterile fill-finishmedium
Polpharma BiologicsJune 2025 demerger: biosimilars brand stays as Polpharma Biologics (operating from Switzerland); the CDMO becomes Rezon Bio.GdańskFamily-ownedPolpharmaTier 3~US$18–100 m est.Biologics and biosimilars, Monoclonal antibody, Microbial and proteinlow
Pure BiologicsAntibody/aptamer discovery + protein production (CRO).WrocławListedTier 3~US$15 m est.Monoclonal antibody, Biologics and biosimilarsmedium
Rezon BioCDMO carved out of Polpharma Biologics (June 2025); positions to be Europe's most cost-competitive CDMO.GdańskFamily-ownedPolpharmaTier 3n/dBiologics and biosimilars, Monoclonal antibody, Microbial and proteinlow
SelvitaCRO drug-discovery house with a growing CDMO/analytical arm (via the PozLab acquisition).KrakówListedTier 3€80.4 m (2024)Small-molecule APIhigh
Synthaverse (Biomed-Lublin)BCG vaccines + immunoglobulins + probiotics.LublinListedTier 3~US$14 m est.Viral vector and vaccine, Biologics and biosimilarsmedium
SyVento BioTechGreenfield mRNA/LNP CDMO; MIA obtained 31 July 2025.SkawinaFamily-ownedTier 3early-stagemRNA and LNPlow

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists